<DOC>
	<DOCNO>NCT00770848</DOCNO>
	<brief_summary>The primary objective study follow : Phase 1b : To identify safe dose level AMG 102 , 15 mg/kg Q3W , combine mitoxantrone prednisone ( MP ) Phase 2 : To estimate adequate precision effect addition AMG 102 MP , compare placebo plus MP , assess hazard ratio ( HR ) overall survival ( OS ) previously treat subject castrate-resistant prostate cancer ( CRPC )</brief_summary>
	<brief_title>AMG 102 Combination With Mitoxantrone Prednisone Subjects With Previously Treated Castrate Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Pathologically confirm adenocarcinoma prostate Radiographic evidence metastatic disease Progressive disease meeting least one follow criterion : 1. sequence least 2 rise PSA value measure minimum 1 week apart 2 ng/mL minimum start value , 2. progression accord RECIST criterion measurable lesion , 3. appearance 2 new lesion bone scan . History prior taxanebased chemotherapy metastatic prostate cancer For patient without history surgical castration , continue GnRH analog administration require ECOG Performance status 0 1 Life expectancy ≥ 3 month Treatment external beam radiotherapy ≤ 14 day enrollment radiopharmaceutical ≤8 week ≤ 4 week since receipt recent prior chemotherapy , nonGnRH analog hormonal therapy ( except continue corticosteroid ) systemic therapy treat prostate cancer &lt; 6 week since receipt prior bevacizumab . Known CNS metastasis ( epidural disease allow treated progression treat area ) . Significant cardiovascular disease LVEF &lt; 50 % MUGA ECHO Treatment infection systemic antiinfectives within 7 day enrollment ( exception uncomplicated urinary tract infection ) Concurrent prior ( within 7 day enrollment ) anticoagulation therapy , except use low dose coumarintype anticoagulant heparins prophylaxis central venous catheter thrombosis allow Major surgical procedure ≤30 day enrollment yet recover prior major surgery Presence peripheral edema &gt; Grade 2 Known positive test HIV , hepatitis C , chronic active hepatitis B Serious nonhealing wound Unable begin protocol specify treatment within 7 day enrollment Other investigational procedure exclude .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>CRPC</keyword>
</DOC>